North Star Asset Management Inc. Has $5.86 Million Stock Position in Edwards Lifesciences Corporation $EW

North Star Asset Management Inc. lifted its position in Edwards Lifesciences Corporation (NYSE:EW) by 15.0% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 68,721 shares of the medical research company’s stock after purchasing an additional 8,940 shares during the period. North Star Asset Management Inc.’s holdings in Edwards Lifesciences were worth $5,858,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $1,626,000. Prospera Financial Services Inc acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $230,000. Coldstream Capital Management Inc. lifted its stake in shares of Edwards Lifesciences by 2.7% in the fourth quarter. Coldstream Capital Management Inc. now owns 9,608 shares of the medical research company’s stock worth $819,000 after buying an additional 249 shares during the last quarter. CFO4Life Group LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $311,000. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Edwards Lifesciences by 11.5% in the fourth quarter. EverSource Wealth Advisors LLC now owns 4,918 shares of the medical research company’s stock worth $419,000 after buying an additional 508 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on EW shares. Robert W. Baird boosted their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. BTIG Research boosted their target price on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. UBS Group reaffirmed a “neutral” rating and set a $94.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Finally, Wells Fargo & Company boosted their target price on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.65.

Edwards Lifesciences Trading Up 3.3%

Shares of EW stock opened at $85.93 on Friday. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $87.89. The firm’s fifty day simple moving average is $81.42 and its 200 day simple moving average is $82.89. The firm has a market capitalization of $49.48 billion, a P/E ratio of 45.71, a price-to-earnings-growth ratio of 2.15 and a beta of 0.87. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. Edwards Lifesciences’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the sale, the chief financial officer owned 39,699 shares of the company’s stock, valued at $3,177,507.96. The trade was a 24.67% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 9,968 shares of the business’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $82.07, for a total transaction of $818,073.76. Following the completion of the sale, the vice president directly owned 22,798 shares in the company, valued at $1,871,031.86. This trade represents a 30.42% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 106,684 shares of company stock valued at $8,811,739 in the last 90 days. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.